 Various drugs that are under research to treat AD include Bapineuzumab, Solanezumab, and Gautenerumab.Bapineuzumab, a humanized anti-aβ MAB, is directed against the N-terminus of Aβ.Phase II clinical trials of Bapineuzumab in mild to moderate AD patients resulted in reduced Aβ concentration in the brain.